Tandem and Abbott collaborate on insulin delivery system that incorporates a glucose-ketone sensor
In a significant move for diabetes management, Abbott and Tandem Diabetes Care have announced a partnership to integrate ketone sensing into automated insulin delivery systems. This development, which is set to revolutionise diabetes care, will utilise Abbott's upcoming dual glucose-ketone sensor, planned for launch in 2026 [2][3][4].
The partnership, which also includes other pump manufacturers, is part of Abbott's broader strategy to develop a dual analyte sensor that measures both glucose and ketones [1][2]. Tandem, in turn, has publicly stated its intentions to integrate their pumps with Abbott's continuous sensor monitoring of glucose and ketones.
Tandem's focus is on ensuring its systems will integrate seamlessly with and support users who adopt Abbott's glucose-ketone sensor once it becomes available. The company is working on a tubeless feature for its more compact Mobi insulin pump and is developing a patch-pump for its insulin delivery systems [5].
Sequel MedTech is also preparing for the U.S. launch of its Twiist AID system, which will integrate with Abbott's planned glucose-ketone sensor [6]. Meanwhile, Abbott has also partnered with Medtronic to develop a continuous glucose monitoring system that works exclusively with its insulin pumps and pens [7].
The ability to detect rising ketone levels can help people with diabetes avoid a life-threatening condition called diabetic ketoacidosis. This condition occurs when the body doesn't have enough insulin to use blood sugar as energy, leading to a buildup of ketones. The integration of ketone sensing into automated insulin delivery systems is expected to significantly improve diabetes management and patient safety.
While specific details about the timing and integration of the new ketone sensing feature have not been shared for Tandem's systems, it is anticipated that official system availability integrating ketone sensing with Tandem's automated insulin delivery systems will occur in 2026 or shortly thereafter [2][3][4]. No specific month or quarter has been disclosed yet, but late 2025 announcements and 2026 launch timelines are consistent across sources.
Abbott announced plans to develop a glucose-ketone sensor in 2022 [8], marking a significant step forward in the company's commitment to innovative diabetes care solutions. This partnership with Tandem Diabetes Care is another testament to Abbott's ongoing efforts to improve diabetes management and provide patients with the tools they need to better manage their condition.
- Devices like Abbott's dual glucose-ketone sensor and Tandem's Mobi insulin pump, designed for diabetes management, are being integrated with analytics to revolutionize care.
- Medtech companies such as Sequel MedTech are also developing systems, like the Twiist AID system, to integrate with Abbott's upcoming glucose-ketone sensor.
- In the health-and-wellness sector, news about partnerships, such as the one between Abbott and Tandem Diabetes Care, focuses on AI-driven medtech advancements to help manage medical-conditions like diabetes.
- Nutrition plays a crucial role in diabetes management; integrating ketone sensing into automated insulin delivery systems can help detect rising ketone levels, improving patient safety and effectively managing the condition.
- Beyond diabetes, these advancements in medtech and analytics also signal a broader commitment by companies like Abbott to provide innovative solutions for various health-related needs.
